Breaking News

Cellusion, Minaris Enter LOI for Manufacturing Process for Cell Therapy

Will develop the manufacturing process of Cellusion’s leading program, CLS001, a novel regenerative medicine product for bullous keratopathy treatment.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Cellusion, a Japanese regenerative medicine startup, and Minaris Regenerative Medicine, a global CDMO, announced Letter of Intent (LOI) for the manufacturing of CLS001 for a Corneal Endothelial Cell Regenerative therapy in the U.S.   The companies will develop the manufacturing process of Cellusion’s leading program, CLS001, a novel regenerative medicine product for bullous keratopathy treatment. Minaris’ Allendale, NJ team will perform process optimization to meet FDA requirements. “We are...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters